On 24 July 2026, The Stock Exchange of Hong Kong Limited (Exchange) published its Consultation Conclusions on Competitiveness Review of Listing Framework (Consultation Conclusions), responding to its Consultation Paper on Competitiveness Review of Listing Framework issued on 13 March 2026 (Consultation Paper).
The Exchange confirmed it will proceed with all of the proposals set out in the Consultation Paper, with certain modifications and clarifications. The changes are aimed at increasing the Exchange's competitiveness against peer exchanges for listing high growth companies.
The Listing Rules amendments took effect immediately upon publication of the Consultation Conclusions on 24 July 2026, meaning the revised framework already applies to new listing applications and to issuers considering their fundraising options.
This marks the first phase of what the Exchange describes as a broader, phased competitiveness review of Hong Kong's listing regime, with a second phase of proposals expected in a separate consultation in due course.
In this article, we summarise the key changes and consider what they mean in practice for issuers, sponsors and investors.
In brief, the reforms touch four main areas of the Listing Rules:
- Weighted Voting Rights (WVR): lower financial eligibility thresholds, a higher voting ratio cap for large-cap applicants, and a refined and more flexible "innovative company" test;
- Issuers Listed Overseas: lower financial eligibility thresholds for secondary listings and streamlined guidance on converting to a primary listing;
- Initial Listing Requirements: codified guidance on ownership continuity, expanded use of US GAAP, and a new route allowing commercially mature biotech and specialist technology companies' to list under the specialist chapters of the Listing Rules; and
- Confidential Filing: no-public filing extended to all listing applicants, alongside an enhanced Return Mechanism that increases transparency around returned applications.
1. Weighted voting rights: lower entry barriers, more flexibility
Lower financial eligibility thresholds
The Exchange's WVR financial eligibility thresholds are lowered and brought closer in line with other markets with tailored WVR requirements.
The expected market capitalisation threshold of both eligibility tests has been lowered. WVR Test A falls from an expected market capitalisation of at least HK$40 billion to at least HK$20 billion, while WVR Test B falls from at least HK$10 billion expected market capitalisation (and revenue in the most recent audited financial year of at least HK$1 billion) to at least HK$6 billion expected market capitalisation (and revenue in the most recent audited financial year of at least HK$600 million). The same reduced thresholds will apply to secondary listings by overseas issuers with WVR structures, aligning them with the primary listing regime.
The Exchange noted that these thresholds remain considerably higher than the ordinary Main Board listing requirements and broadly align Hong Kong with the Shanghai Stock Exchange and the Shenzhen Stock Exchange, and rejected calls from some respondents to lower them further or to reserve the reduced Test B thresholds for technology-led applicants only.
Higher WVR ratio cap for large-cap applicants
Applicants with an expected market capitalisation of at least HK$40 billion at the time of listing will be able to adopt a weighted voting ratio of up to 20:1, doubling the current 10:1 cap. This will not extend to existing listed WVR issuers, consistent with the existing rule preventing an increase in the proportion of WVR shares after listing. The Exchange also confirmed a more flexible minimum economic interest test: it may accept a lower minimum underlying economic interest for WVR beneficiaries (as low as 5% of total issued share capital, excluding treasury shares) provided that the interest is at least HK$4 billion at the time of listing.
Some respondents flagged that, combined, these two changes could in the most extreme case allow a WVR beneficiary holding only 5% of the economic interest to control 51% of the votes. The Exchange acknowledged this but considered the absolute HK$4 billion floor, together with existing corporate governance safeguards (including the Corporate Governance Committee and event-based sunset provisions), to be sufficient protection, and declined to introduce a time-based sunset clause or other new governance conditions at this stage.
A more flexible "innovative company" test
Perhaps the most structurally significant change is the refinement of the innovative company requirements into two distinct routes:
- Route A (technology): the applicant adopts technology that is novel, or essential to the novelty of its core business, assessed against the R&D, IP and Outsized Market Cap Characteristics (an applicant must satisfy more than one); and
- Route B (business model: the applicant's success is attributable to a new business model, which need not be enabled by novel technology, assessed against a new CAGR Growth Characteristic and an Industry Position Characteristic. The CAGR Growth Characteristic requires the applicant to have a revenue compound annual growth rate (CAGR) of at least 30% over the track record period, calculated by reference to annual revenue over the three financial years of the applicant's track record period, with flexibility to rely on alternative operational metrics in appropriate cases, whereas the Industry Position Characteristic requires the applicant to have a relatively prominent position in its industry.
Both routes retain the existing Novelty Characteristic, which now expressly recognises that an applicant may be "one of the first few" in its industry to adopt a new technology or business model, rather than needing to be the sole first mover. The Exchange also confirmed it will expand the scope of applicants presumed to meet the innovative company requirements to include "Qualified Biotech Applicants" and "Qualified Specialist Technology Applicants" that have commercialised their Core Products (as defined in Chapter 18A of the Listing Rules) but have not sought a listing under the specialist chapters.
The categories of applicants presumed to meet the innovative company requirements have also been expanded to cover applicants that are Qualified Biotech Applicants and Qualified Specialist Technology Applicants. Qualified Biotech Applicants refer to applicants that (i) operate in the biotech industry, have been primarily engaged in the R&D of at least one Core Product, and have commercialised that product; (ii) have continued the R&D of the Core Product during the 12 months prior to listing; and (iii) have ownership of IP rights relating to the Core Product. Qualified Specialist Technology Applicants refer to applicants that (i) are primarily engaged in the R&D of, and have commercialised, Specialist Technology Product(s) within an acceptable sector of a specialist technology industry; and (ii) meet the R&D expenditure percentage test designed for a commercial company under Chapter 18C.
On external validation, the Exchange will provide guidance aligning the meaning of "sophisticated investor" with existing guidance for SPACs and Specialist Technology Companies, and will introduce a 10% aggregate investment threshold (assessed on an aggregate, rather than per-investor, basis) to demonstrate "meaningful third-party investment" for Route B applicants specifically. No quantitative threshold applies to Route A.
2. Issuers listed overseas: an easier path home
For secondary listing applicants with a WVR structure, the lower financial eligibility thresholds set out in section 1 above apply.
For secondary listing applicants without a WVR structure, the market capitalisation threshold under Criteria B (a two-year compliant track record on a Qualifying Exchange) falls from HK$10 billion to HK$6 billion. The Exchange will retain the HK$3 billion threshold under Criteria A (a five-year track record on a Qualifying Exchange or a Recognised Stock Exchange), taking the view that the longer track record already justifies the lower financial bar and declining to consolidate the two tests into a single set of criteria.
The Exchange will also publish streamlined guidance on the process for converting a secondary listing into a (dual) primary listing, setting out the typical steps and timelines involved, though the underlying substantive requirements are unchanged.
Despite the suggestions of some respondents, the Exchange has not adopted further facilitative measures for overseas issuers at this stage, noting that a broader review of continuing obligations for listed issuers is under way as part of the second phase of the competitiveness review, and confirmed the list of Recognised Stock Exchanges will continue to be reviewed and expanded on an ongoing basis.
3. Initial listing requirements and listing arrangements
Ownership continuity and control
The Exchange will codify its existing guidance into a Listing Rule requirement that an applicant satisfies the ownership continuity and control requirement if it can demonstrate no material change in influence on management during the relevant period, despite a change in controlling shareholder. This is intended to formalise existing practice rather than introduce a new substantive test, and the Exchange retains discretion to reject applications that raise genuine packaging concerns.
Financial reporting standards
Reporting using the Generally Accepted Accounting Principles in the United States of America (US GAAP) will be permitted more widely. In addition to issuers listed or to be listed in the US, subsidiaries of US-listed parents and companies with substantial US business operations will be able to apply to use US GAAP, subject to the usual Reconciliation Statement and disclosure of material differences. Two related compliance burdens will be removed: issuers will no longer need to revert to the Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS) if they subsequently delist from a US exchange, and unaudited Reconciliation Statements will no longer require auditor review (though audit committee review will still apply, and a full audit remains required for annual accounts).
A route to the specialist chapters for commercially mature applicants
Biotech Companies and Specialist Technology Companies (as defined in the Listing Rules) that have grown to the point of satisfying the ordinary Main Board financial eligibility tests will, for the first time, be permitted to list under Chapter 18A or 18C rather than being pushed into the ordinary listing route. A number of requirements designed for pre-revenue or early-stage companies (the third-party investment requirement, prescribed warning statements, use-of-proceeds restrictions and the shorter remedial period for insufficient operations) will not apply to these "Eligible Specialist Companies", while the Biotech track record period is extended to three financial years to reflect their greater maturity. Importantly, these companies will still need to satisfy the full Chapter 8A suitability assessment if they also wish to list with a WVR structure, so this change does not create a shortcut into WVR listings.
4. Confidential filing becomes the default option
All new listing applicants, not just secondary listing applicants, Biotech Companies and Specialist Technology Companies, will now be able to choose not to publish their Application Proof at the time of filing. Instead, they will only be required to publish an Offer Clearance Announcement on the same date as their Post Hearing Information Pack (PHIP). The Exchange has also removed its existing guidance requiring applicants to maintain confidentiality until PHIP publication, and will instead refer to this option as "non-public filing" rather than "confidential filing". Applicants that wish to publish their draft listing document before the PHIP stage, for example to support broader investor outreach, may do so voluntarily as an "Updated Application Proof", subject to appropriate warning statements.
As a counterbalance, the Return Mechanism will be enhanced. Where an application is returned as not substantially complete, the Exchange will publish, alongside the sponsor's identity, the names and roles of the other professional parties responsible for the Application Materials (including legal advisers to the company and to the sponsor, reporting accountants, auditors and other named experts) and the reasons for the return. The Exchange was clear that this disclosure is intended to promote transparency rather than to attribute fault, and does not alter the existing allocation of regulatory responsibility between issuers, sponsors and other advisers. Separately, the eight-week moratorium following a return will now run from the later of the conclusion of any review process or the expiry of the time to invoke one, rather than from the date of the original decision, preserving its deterrent effect for applicants that seek a review.
Looking ahead
Issuers with active listing applications as at 24 July 2026 seeking a listing under Chapter 8 may apply to amend those applications, through their sponsors, to be considered instead under Chapter 8A (WVR) and/or Chapter 18A or 18C (Biotech or Specialist Technology), without needing to withdraw and refile. The Exchange has published updated guidance in its Guide for New Listing Applicants to reflect all of the above changes.
This is only the first phase of the Exchange's competitiveness review. A second consultation paper is expected in due course, likely to address, among other things, the continuing obligations of listed issuers and further facilitative measures for issuers listed overseas. We will continue to monitor developments and will provide a further update once the next phase of proposals is published.
Should you have any questions on how these changes may affect a prospective listing, please get in touch with one of the contacts on the right-hand side of this page or your usual Simmons & Simmons contact.
